权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Multifunctional Nanotechnology Platform for Triple Negative Breast Cancer Treatment

用于三阴性乳腺癌治疗的多功能纳米技术平台

基本信息

批准号：
10672232
负责人：
EMMANUEL O AKALA
金额：
$ 15.45万
依托单位：
HOWARD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10672232
关键词：
ABCB1 gene Abraxane Acceleration Adjuvant African American Antibodies Biodistribution Breast Cancer Cell Breast Cancer Patient Breast Cancer Treatment Breast Cancer cell line Bypass Carboplatin Cells Cetuximab Circulation Clinic Clinical Research Combination Drug Therapy Confocal Microscopy Coupled Cytotoxic agent Data Reporting Development Disease Dose Drug Combinations Drug Delivery Systems Drug Efflux Drug Kinetics Dyes ERBB2 gene Epidermal Growth Factor Receptor Ethnic Population Event FDA approved Female Fluorescent Dyes Goals Grant Hispanic Immunotherapy Implant In Vitro In complete remission Label Link Literature Liver MDA MB 231 Mediating Medical Molecular Monoclonal Antibodies Morphology Multi-Drug Resistance Mus Nanotechnology Neoadjuvant Therapy Neoplasm Metastasis Nude Mice Numbness Outcome Paclitaxel Pain Particle Size Pathologic Patient-Focused Outcomes Patients Peripheral Nervous System Diseases Persons Pharmaceutical Preparations Phase Platinum Polymers Prior Chemotherapy Prognosis Proteins Recurrent disease Regimen Relapse Resistance Rhodamine 123 SN-38 Site Structure Surface Therapeutic Therapeutic Effect Time Toxic effect Tumor Biology Vertebral column Visceral metastasis Woman Work Xenograft Model antibody conjugate biodegradable polymer cancer cell chemotherapeutic agent chemotherapy crosslink cytotoxicity drug efficacy drug release kinetics efficacy evaluation efficacy study fabrication improved in vivo interest malignant breast neoplasm molecular targeted therapies nanoparticle nanopolymer nanotechnology platform older women overexpression poly(lactide)prevent programmed cell death ligand 1 racial population receptor response standard of care subcutaneous systemic toxicity targeted agent targeted delivery targeted treatment taxane triple-negative invasive breast carcinoma tumor young woman zeta potential

项目摘要

Project Summary: Triple-negative breast cancer (TNBC) accounts for approximately 15% of invasive breast cancers and is associated with aggressive tumor biology, poor prognosis, resistance, visceral metastases and earlier disease recurrence. TNBC is more common in younger women than in older women and in African- American and Hispanic women. Platinum-based drugs showed higher sensitivity in TNBC compared to non- TNBC patients and recently there has been a renewed interest for platinum therapy in TNBC, especially combination of carboplatin with paclitaxel (PTX). Sacituzumab govitecan is made up of an anti–Trop-2 antibody linked to the chemotherapy drug (SN-38) and was cleared by the FDA for TNBC patients who have undergone at least two prior chemotherapies. The FDA granted an accelerated approval for the immunotherapy drug atezolizumab in combination with chemotherapy (nab-paclitaxel) for the treatment of TNBC (for tumors positive for PD-L1). Thus chemotherapy is important in the therapeutic management of TNBC even in the advent of immunotherapy and targeted therapy. However, chemotherapies are known to cause fatal peripheral neuropathy in addition to poor response, metastasis, relapse and development of multidrug resistance. The goal of this application is the development of multifunctional targeted nanoparticles capable of achieving better outcomes for TNBC patients: (a) targeted delivery of large doses of multiple drugs into cancer cells (per a single biorecognition event compared to a single immunotargeted drug (e.g. sacituzumab govitecan-hziy)) to maximize therapeutic effects while reducing systemic toxicity (off target toxicity); (b) EGFR-receptor targeted nanoparticles that promote intracellular drug delivery and release and which can bypass multidrug resistant protein (p-glycoprotein) which mediates efflux of drug molecules; (c) capable of long circulation without being sequestered into the liver. EGFR is overexpressed by TNBC and literature is replete with examples of the use of cetuximab in therapy by targeting EFGR. We hypothesize that the development of biodegradable polymeric nanotechnology platform containing carboplatin and paclitaxel in the core and using cetuximab (tagged on nanoparticle surface) as a targeting moiety will improve TNBC patients’ outcomes, unlike repeated chemotherapy cycles with high doses of cytotoxic drugs. We hypothesize that the dual-loaded multifunctional targeted nanoparticles will be active in vitro and show in vivo efficacy in mouse xenograft models of TNBC positive tumors. Aim #1: Fabrication of polymeric dye-loaded and-paclitaxel and carboplatin-loaded stealth hydrolysable crosslinked cetuximab surface-targeted polylactide (PLL) nanoparticles. Aim #2: Characterization of anti-EGFR mAb (cetuximab) surface-targeted-PLL-nanoparticles containing carboplatin and paclitaxel in the core. Aim #3: Biodistribution and efficacy studies in tumor-bearing mice. This work will bring to bear the combined power of chemotherapeutic agents, molecular targeted therapy and nanotechnology to overcome EGFR positive TNBC resistance and improve efficacy with minimal toxicity.

项目总结：三阴性乳腺癌（TNBC）约占浸润性乳腺癌的15%